Phosphoramidate derivatives of 2',3'-didehydro-2',3'-dideoxyadenosine [d4A] have markedly improved anti-HIV potency and selectivity

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 19, 1996, Pages 2359-2362

  McGuigan, Christopher ^b   Wedgwood, Orson M ^a   De Clercq, Erik ^b   Balzarini, Jan ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; ANTIVIRUS AGENT; NUCLEOSIDE DERIVATIVE; PHOSPHORAMIDIC ACID DERIVATIVE; PRODRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; MOLONEY MURINE SARCOMA ONCOVIRUS; NUCLEAR MAGNETIC RESONANCE;

EID: 0030575614     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00433-7     Document Type: Article

References (21)

1. 1. Mitsuya, H.; Broder, S. Proc. Natl. Acad. Sci. USA 1986, 83, 1911.
2. 2. Baba, M.; Pauwels, R.; Herdewijn, P.; De Clercq, E.; Desmyter, J.; Vandeputte, M. Biochem. Biophys. Res. Commun. 1967, 142, 128.
3. 3. Balzarini, J.; Kang, G.-J.; Dalai, M.; Herdewijn, P.; De Clercq, E.; Broder, S.; Johns, D.G. Mol. Pharmacol. 1987, 32, 162.
4. 4. McGuigan, C.; Tollerfield, S.M.; Riley, P.A. Nucleic Acids Res. 1989, 17, 6065; Jones, B.C.N.M.; McGuigan, C.; Riley, P.A. ibid 1989, 17, 7195.
5. 4. McGuigan, C.; Tollerfield, S.M.; Riley, P.A. Nucleic Acids Res. 1989, 17, 6065; Jones, B.C.N.M.; McGuigan, C.; Riley, P.A. ibid 1989, 17, 7195.
6. 5. Farrow, S.N.; Jones, A.S.; Kumar, A.; Walker, R.T.; Balzarini, J.; De Clercq, E. J. Med. Chem. 1990, 33, 1400.
7. 6. Perigaud, C.; Aubertin, A.M.; Peliano, H.; Giradet, J.L.; Maury, G.; Gosselin, G.; Kim, A.; Imbach, J.L. Biochem. Pharmacol. 1994, 48, 11.
8. 7. Cooney, D.A.; Ahluwalia, G.; Mitsuya, H.; Fridland, A.; Johnson, M.; Hao, Z.; Dalal, M.; Balzarini, J.; Broder, S.; Johns, D.G. Biochem. Pharmacol. 1987, 36, 1765.
9. 8. McGuigan, C.; Sheeka, H.M.; Mahmood, N.; Hay, A. Bioorg. Med. Chem. Lett. 1993, 3, 1203.
10. 9. McGuigan, C.; Pathirana, R.N.; Balzarini, J.; De Clercq, E. J. Med. Chem. 1993, 36, 1048.
11. 10. McGuigan, C.; Jones, B.C.N.M.; Devine, K.G.; Nicholls, S.R.; O'Connor, T.J.; Kinchington, D. Bioorg. Med. Chem. Lett. 1991, 1, 729.
12. 11. Talekar, R.R.; Coe, P.L.; Walker, R.T. Synthesis, 1993, 303.
13. 12. Uchiyama, M.; Aso, Y.; Noyori, R.; Hayakawa, Y. J. Org. Chem. 1993, 58, 373.
14. 13. Mark, V.; Dungan, C.H.; Crutchfield, M.M.; Van Wazer, J.R. Compilation of 31P NMR data; Grayson, M.; Griffith, E.J. Ed.; Topics in Phosphorus Chemistry, vol. 5, Wiley, New York, 1969.
15. 14. McGuigan, C.; Pathirana, R.N.; Mahmood, N.; Devine, K.G.; Hay, A.J. Antiviral Res., 1992, 17, 311.
16. +, calculated 475.149].
17. 16. McGuigan, C.; Pathirana, R.N.; Choi, S.S.-M.; Kinchington, D.; O'Connor, T.J. Antiviral Chem. Chemother. 1993, 4, 97.
18. 17. McGuigan, C.; Cahard, D.; Sheeka, H.M.; De Clercq, E.; Balzarini, J. BioMed. Chem. Lett. 1996, 6, 1183.
19. 18. McGuigan, C.; Nicholls, S.R.; O'Connor, T.J.; Kinchington, D. Antiviral Chem. Chemother. 1990, 1, 25.
20. 19. McGuigan, C.; Bellevergue, P. ; Sheeka, H.; Mahmood, N.; Hay A.J. FEBS Lett. 1994, 351, 11.
21. 50 is the drug concentration which reduces the viability of uninfected cells by 50%. MIC is the drug concentration which causes a microscopically visible alteration of cell morphology. Data are given for HIV-1 and HIV-2-induced cytopathicity in CEM cells and MSV [moloney murine sarcoma virus]-induced transformation of murine embryo fibroblast C3H cells.